Skip to main content

Table 8 Comparison of TP53 mutations and clinicopathologic features

From: Prognostic role of serum p53 antibodies in lung cancer

  No. of cases No. of patients with TP53 mutations
Age (years)   
≤60 12 4 (33.3%)
>60 53 12 (22.7%)
Total 65 16 (24.6%)
Sex   
Male 51 12 (23.5%)
Female 14 4 (28.6%)
Total 65 16 (24.6%)
Histologic type   
NSCLC   
Adenocarcinoma 27 6 (22.2%)
Squamous cell carcinoma 27 8 (29.6%)
Bronchioloalveolar carcinoma 2 0 (0%)
Large cell carcinoma 4 1 (25.0%)
Anaplastic carcinoma 2 1 (50.0%)
Mixed carcinoma 2 0 (0%)
SCLC 1 0 (0%)
Total 65 16 (24.6%)
NSCLC stage   
I 41 10 (24.4%)
II 9 6 (66.7%)
III 10 0 (0%)
IV 4 0 (0%)
Total 64 16 (25.0%)
NSCLC grade   
G1-G2 28 5 (17.9%)
G3 35 11 (31.4%)
Missing 1 0 (0%)
Total 64 16 (25.0%)